Navigation Links
Viagra could reduce multiple sclerosis symptoms
Date:5/19/2011

Universitat Autnoma de Barcelona researchers have discovered that Viagra drastically reduces multiple sclerosis symptoms in animal models with the disease. The research, published in Acta Neuropathologica, demonstrates that a practically complete recovery occurs in 50% of the animals after eight days of treatment. Researchers are confident that clinical trials soon will be carried out in patients given that the drug is well tolerated and has been used to treat sexual dysfunction in some multiple sclerosis patients.

Multiple sclerosis is the most common chronic inflammatory disease of the central nervous system and one of the main causes of disability among young adults. The disease is caused by the presence of multiple focuses of demyelination (loss of myelin sheaths around the axons, affecting the ability of neurons to communicate) and neurodegeneration in different areas of the central nervous system. There is currently no cure for the disease, although some drugs have proven effective in fighting symptoms and preventing it from progressing.

A research team from the UAB Institute of Biotechnology and Biomedicine directed by Dr Agustina Garca, in collaboration with the research team directed by Dr Juan Hidalgo from the UAB Institute of Neurosciences, has studied the effects of a treatment using sildenafil, sold as Viagra, in an animal model of multiple sclerosis known as experimental autoimmune encephalomyelitis (EAE). Researchers demonstrated that a daily treatment with sildenafil after disease onset quickly reduced clinical signs, with a practically complete recovery in 50% of the cases after eight days of treatment. Scientists observed how the drug reduced the infiltration of inflammatory cells into the white matter of the spinal cord, thus reducing damage to the nerve cell's axon and facilitating myelin repair.

Sidenafil, together with tadalafil (Cialis) and vardenafil (Levitra), form part of a group of vasodilator drugs known as phosphodiesterase type 5 (PDE5) inhibitors, used in the treatment of erectile dysfunction and pulmonary arterial hypertension. Recent studies in animal models of central nervous system pathologies already pointed to the fact that in addition to vasodilation, these drugs could contain other neuroprotective actions and suggest their usefulness as possible treatments of both acute (cerebrovascular stroke) and chronic (Alzheimer's) neuropathologies. In fact, in a research published in 2010 in the Journal of Neurochemistry, the same research group from UAB demonstrated that one of these inhibitors reduced neuroinflammation and neuronal damage in animal models of traumatic brain injury.


'/>"/>

Contact: Agustina Garcia
Agustina.garcia@uab.cat
34-935-812-802
Universitat Autonoma de Barcelona
Source:Eurekalert  

Related medicine news :

1. Pediatricians Want to Restrict Ads for Tobacco, Booze, Viagra
2. Drugs Like Viagra Linked to Higher Rates of STDs
3. FDA Panel Votes Against Approval of Female Viagra
4. FDA Panel Weighs OK of Female Viagra
5. Viagra Linked to Hearing Loss
6. Viagra May Aid Those With Lung Fibrosis
7. UAB study examines hearing loss, Viagra use
8. Study Explores Possibility of a Female Viagra
9. Implant jab could solve the misery of back pain
10. Simple fitness test could predict long-term risk for heart attack, stroke in middle-aged people
11. Half of prostate cancers could potentially benefit from new type of cancer drugs, U-M study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Viagra could reduce multiple sclerosis symptoms
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease ... will be participating in Rare Disease Day events, hosted by the Rare Disease ... Disease Report, a website, weekly e-newsletter and quarterly publication, will be conducting interviews ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information ... National Institute for Health and Care Excellence (NICE) framework. The agreement ... Health Service (NHS) to search, order and purchase medical and healthcare-related content through ...
(Date:2/23/2017)... ... 23, 2017 , ... Current Meditation , a new ... throughout the U.S. starting this spring. Current Meditation focuses on “meditation for the ... Current Meditation will be the first meditation concept in the U.S. offering franchising ...
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Top ... Smiling Patriot program today with a new Indiegogo campaign . Individuals ... to homeless veterans in the Los Angeles area, either as a participating patient or ...
(Date:2/22/2017)... New York (PRWEB) , ... February 22, 2017 ... ... floor entrance and lobby of a new healthcare contact center in Georgia, PENETRON ... , One of the nation’s largest healthcare systems recently invested $51 million to ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... The top three players dominating ... Koninklijke Philips N.V., and Schiller. Collectively, these companies held ... in 2015. Strong product portfolio and a monumental geographical ... aiding these players remain leaders in the fragmented competitive ... the global market are likely to focus on mergers ...
(Date:2/23/2017)... February 23, 2017 Tillotts Pharma ... Berlin office was opened in ... . The portfolio includes Entocort ® for the ... treatment of ulcerative colitis, and VistaPrep ® for ... Swiss specialty pharmaceutical company focused on the treatment of ...
(Date:2/23/2017)... and VANCOUVER, British Columbia , ... OGXI ) today announced its year end 2016 ... In January 2017, OncoGenex, and Achieve Life Science, Inc., ... have entered into a definitive merger agreement under which ... completion of the proposed merger, Achieve,s stockholders are expected ...
Breaking Medicine Technology: